Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NSD9
UPID:
SYFB_HUMAN
Alternative names:
Phenylalanyl-tRNA synthetase beta subunit
Alternative UPACC:
Q9NSD9; B4DFM0; O95708; Q4ZFX1; Q57ZJ5; Q9NZZ6
Background:
The Phenylalanine--tRNA ligase beta subunit, also known as the Phenylalanyl-tRNA synthetase beta subunit, plays a crucial role in protein synthesis by attaching phenylalanine to its corresponding tRNA. This process is vital for the accurate translation of mRNA into protein, ensuring that proteins are correctly assembled with the appropriate amino acids.
Therapeutic significance:
Understanding the role of Phenylalanine--tRNA ligase beta subunit could open doors to potential therapeutic strategies. Its direct involvement in Rajab interstitial lung disease with brain calcifications 1, a severe neurodevelopmental disorder, highlights its significance in human health and disease. Targeting this protein could offer new avenues for treating or managing this debilitating condition.